TIGIT-related Transcriptome Profile and Its Association with Tumor Immune Microenvironment in Breast Cancer

Overview

Journal Biosci Rep

Specialty Cell Biology

Date 2021 Mar 15

PMID 33721026

Citations 12

Authors

Qin Zhang

Chaowei Gao

Jianqiang Shao

Zunyi Wang

Affiliations

Soon will be listed here.

Abstract

Immune checkpoints are intensively investigated as targets in cancer immunotherapy. T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) are recently emerging as a novel promising target in cancer immunotherapy. Herein, we systematically investigated TIGIT-related transcriptome profile and relevant clinical information derived from a total of 2994 breast cancer patients recorded in The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). We uncovered the relationship between TIGIT and major molecular and clinical characteristics in breast cancer. More importantly, we depicted the landscape of associations between TIGIT and other immune cell populations. Gene ontology analyses and Gene Set Variation Analysis (GSVA) of genes correlated with TIGIT revealed that TIGIT were mainly involved in immune responses and inflammatory activities. In summary, TIGIT expression was tightly related to the aggressiveness of breast cancer; TIGIT might manipulate anti-tumor immune responses by impacting not only T cells but also other immune cells. To the best of our knowledge, this is by far the most comprehensive and largest study characterizing the molecular and clinical features of TIGIT in breast cancer through large-scale transcriptome data.

Citing Articles

Low expression of TOX predicts poor prognosis of patients with breast cancer in the real world: A retrospective study.

Tan C, Wu D, Yang X, Zhang S, Liu S, Yu B Heliyon. 2025; 11(1):e41180.

PMID: 39758401 PMC: 11699305. DOI: 10.1016/j.heliyon.2024.e41180.

Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.

Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F Med Oncol. 2024; 42(1):36.

PMID: 39719469 DOI: 10.1007/s12032-024-02588-y.

CD8 T cell exhaustion in the tumor microenvironment of breast cancer.

Xie H, Xi X, Lei T, Liu H, Xia Z Front Immunol. 2024; 15:1507283.

PMID: 39717767 PMC: 11663851. DOI: 10.3389/fimmu.2024.1507283.

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer.

Sun J, Tian Y, Yang C Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):231-241.

PMID: 39158733 DOI: 10.1007/s00210-024-03346-7.

Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond.

Zhou Z, Wang J, Wang J, Yang S, Wang R, Zhang G Mol Cancer. 2024; 23(1):131.

PMID: 38918817 PMC: 11201788. DOI: 10.1186/s12943-024-02047-2.

References

Stamm H, Oliveira-Ferrer L, Grossjohann E, Muschhammer J, Thaden V, Brauneck F . Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology. 2019; 8(12):e1674605. PMC: 6844319. DOI: 10.1080/2162402X.2019.1674605. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Bersanelli M, Buti S . From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol. 2017; 8(1):37-53. PMC: 5309713. DOI: 10.5306/wjco.v8.i1.37. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Yu X, Harden K, Gonzalez L, Francesco M, Chiang E, Irving B . The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2008; 10(1):48-57. DOI: 10.1038/ni.1674. View

Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A . The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009; 106(42):17858-63. PMC: 2764881. DOI: 10.1073/pnas.0903474106. View

10.

Li R, Qu H, Wang S, Wei J, Zhang L, Ma R . GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC. Bioinformatics. 2018; 34(14):2515-2517. DOI: 10.1093/bioinformatics/bty124. View

11.

Liu Q, Cheng R, Kong X, Wang Z, Fang Y, Wang J . Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data. Front Immunol. 2020; 11:558757. PMC: 7718028. DOI: 10.3389/fimmu.2020.558757. View

12.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

13.

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

14.

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J . ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014; 58(2-3):234-9. DOI: 10.1007/s12026-014-8516-1. View

15.

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Erratum to: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):249. PMC: 5134277. DOI: 10.1186/s13059-016-1113-y. View

16.

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

17.

Johnston R, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y . The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell. 2014; 26(6):923-937. DOI: 10.1016/j.ccell.2014.10.018. View

18.

Yang Z, Kim H, Wu H, Jalali S, Tang X, Krull J . TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma. Clin Cancer Res. 2020; 26(19):5217-5231. DOI: 10.1158/1078-0432.CCR-20-0558. View

19.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

20.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View